These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 23852452)

  • 21. Identification of differently expressed genes with specific SNP Loci for breast cancer by the integration of SNP and gene expression profiling analyses.
    Yuan P; Liu D; Deng M; Liu J; Wang J; Zhang L; Liu Q; Zhang T; Chen Y; Jin G
    Pathol Oncol Res; 2015 Apr; 21(2):469-75. PubMed ID: 25408372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of c-myc, c-Ha-ras1, and c-erbB-2 proto-oncogenes in normal and malignant human breast epithelial cells.
    Benz CC; Scott GK; Santos GF; Smith HS
    J Natl Cancer Inst; 1989 Nov; 81(22):1704-9. PubMed ID: 2572702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
    Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
    Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of tissue mesodissection to molecular cancer diagnostics.
    Krizman D; Adey N; Parry R
    J Clin Pathol; 2015 Feb; 68(2):166-9. PubMed ID: 25430495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
    Perez K; Walsh R; Brilliant K; Noble L; Yakirevich E; Breese V; Jackson C; Chatterjee D; Pricolo V; Roth L; Shah N; Cataldo T; Safran H; Hixson D; Quesenberry P
    Exp Mol Pathol; 2013 Aug; 95(1):74-82. PubMed ID: 23528430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.
    Sánchez-Muñoz A; Gallego E; de Luque V; Pérez-Rivas LG; Vicioso L; Ribelles N; Lozano J; Alba E
    BMC Cancer; 2010 Apr; 10():136. PubMed ID: 20385028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy.
    Pereira CB; Leal MF; de Souza CR; Montenegro RC; Rey JA; Carvalho AA; Assumpção PP; Khayat AS; Pinto GR; Demachki S; de Arruda Cardoso Smith M; Burbano RR
    PLoS One; 2013; 8(3):e60576. PubMed ID: 23555992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS 3'-UTR variants and stratification of breast-cancer risk.
    Kumar MS; Swanton C
    Lancet Oncol; 2011 Apr; 12(4):318-9. PubMed ID: 21435949
    [No Abstract]   [Full Text] [Related]  

  • 29. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method.
    Yang MJ; Chiu HH; Wang HM; Yen LC; Tsao DA; Hsiao CP; Chen YF; Wang JY; Lin SR
    Ann Surg Oncol; 2010 Feb; 17(2):624-33. PubMed ID: 19937133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
    Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
    Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
    de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
    J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
    [No Abstract]   [Full Text] [Related]  

  • 32. Increased expression of annexin A1 is correlated with K-ras mutation in colorectal cancer.
    Su N; Xu XY; Chen H; Gao WC; Ruan CP; Wang Q; Sun YP
    Tohoku J Exp Med; 2010 Dec; 222(4):243-50. PubMed ID: 21127395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues.
    Lee JH; Daugharthy ER; Scheiman J; Kalhor R; Ferrante TC; Terry R; Turczyk BM; Yang JL; Lee HS; Aach J; Zhang K; Church GM
    Nat Protoc; 2015 Mar; 10(3):442-58. PubMed ID: 25675209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The detection of activating somatic mutations in gene KRAS using pyrosequencing technique].
    Dribnokhodova OP; Mironov KO; Dunaeva EA; Demidova IA; Barinov AA; Boĭtsekhovskaia IaA; Markelov ML; Shipulin GA
    Klin Lab Diagn; 2013 Jun; (6):49-51. PubMed ID: 24340949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression.
    Selamat SA; Chung BS; Girard L; Zhang W; Zhang Y; Campan M; Siegmund KD; Koss MN; Hagen JA; Lam WL; Lam S; Gazdar AF; Laird-Offringa IA
    Genome Res; 2012 Jul; 22(7):1197-211. PubMed ID: 22613842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics.
    Ståhl PL; Salmén F; Vickovic S; Lundmark A; Navarro JF; Magnusson J; Giacomello S; Asp M; Westholm JO; Huss M; Mollbrink A; Linnarsson S; Codeluppi S; Borg Å; Pontén F; Costea PI; Sahlén P; Mulder J; Bergmann O; Lundeberg J; Frisén J
    Science; 2016 Jul; 353(6294):78-82. PubMed ID: 27365449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas.
    García-Inclán C; López F; Pérez-Escuredo J; Cuesta-Albalad MP; Vivanco B; Centeno I; Balbín M; Suárez C; Llorente JL; Hermsen MA
    Cell Oncol (Dordr); 2012 Dec; 35(6):443-50. PubMed ID: 23055340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
    Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
    J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.